A drug to treat advanced kidney cancer has been rejected for use on the NHS in draft guidance, a health watchdog has announced. While evidence shows everolimus (Afinitor) is clinically effective, it is "expensive" and there is limited data on how much it can extend people's lives, said the National Institute for Health and Clinical Excellence (Nice). snip... Novartis offered a risk-sharing scheme to give patients the first treatment pack for free followed by 5% off the cost of subsequent packs but this was rejected. Professor Peter Littlejohns, Nice clinical and public health director, said the draft guidance is open...
